III/IV期非小细胞肺癌放化疗和/或免疫治疗后肺炎的影像学与定量CT特征
这项回顾性单中心研究分析了接受放化疗联合或不联合度伐利尤单抗的III期不可切除非小细胞肺癌患者,以及一线帕博利珠单抗治疗的IV期患者,比较肺炎的影像学模式和定量CT特征。结果显示RT+ICI组肺炎发生率显著更高(47.2%,p<0.001),高级别肺炎更常为双侧、出现更早,并与既存间质性肺病和较低基线弥散功能相关。
要点
- RT+ICI组肺炎发生率47.2%,显著高于RT-only组22.1%和ICI-only组15.5%(p<0.001)。
- 高级别肺炎更常双侧(100% vs 59%,p=0.003)、出现更早(52.5 vs 133.0天,p<0.001)。
- 既存ILD(14% vs 2%,p=0.03)和较低基线DLCO(52.2% vs 71.0%,p=0.004)与高级别肺炎相关。
核心结论
- 接受RT联合ICI治疗的患者肺炎发生率显著更高。
- 高级别肺炎更常为双侧、具有独特影像学模式、出现更早,并与既存ILD和弥散功能降低相关。
- 定量CT分析证实中高剂量肺部照射联合ICI治疗导致更严重的肺损伤。
研究设计与样本
- 回顾性单中心研究,纳入2011-2021年III期不可切除非小细胞肺癌接受放化疗±度伐利尤单抗且发生任何级别肺炎的患者,以及2017-2021年IV期非小细胞肺癌一线帕博利珠单抗治疗后发生肺炎的患者。
- 收集基线和随访临床数据及CT扫描,由放射科医生比较三组CT特征,并比较同一患者不同肺区域及不同治疗组间的定量影像特征。
主要发现
- 71例患者发生肺炎:RT-only组36/163(22.1%),ICI-only组18/116(15.5%),RT+ICI组17/36(47.2%,p<0.001)。
- ICI-only组累及更多肺叶(4.06 vs 3.41 vs 3.21,p=0.03),双侧病变趋势更高(83% vs 65% vs 58%,p=0.06)。
- RT-only组支气管扩张更常见(47% vs 18% vs 6%,p=0.003),ICI-only组实变较少(50% vs 75% vs 75%,p=0.04)。
- 低级别肺炎(<3级)更常与机化性肺炎模式相关(p=0.01)。
- 高级别肺炎危险因素包括既存ILD(14% vs 2%,p=0.03)和较低基线DLCO(52.2±15.3% vs 71.0±21.4%,p=0.004);高级别肺炎出现更早(52.5±49.5 vs 133.0±101.6天,p<0.001)且更常双侧(100% vs 59%,p=0.003)。
临床怎么用
- 对接受RT联合ICI治疗的患者应警惕更高的肺炎风险,尤其是既存ILD或基线DLCO降低者。
- 高级别肺炎出现更早且更常双侧,随访中需关注这些影像特征。
- 定量CT分析可辅助区分放射性肺炎与ICI相关肺炎,高剂量区域损伤更重提示联合治疗协同效应。
局限性
- 回顾性单中心研究,样本量有限(共71例肺炎患者)。
- 三组患者分别来自不同分期和治疗年代,可能存在选择偏倚。
- 未报告盲法评估细节及定量CT分析的重复性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with unresectable stage III non-small cell lung cancer (NSCLC) receive a combination of chemotherapy (CT), thoracic radiation therapy (RT) and immune checkpoint inhibition (ICI). Stage IV NSCLC with a high PD-L1 tumor proportion score receive first line treatment with ICI. These new therapies and combinations can give rise to pneumonitis due to RT but also due to ICI, both etiologies being notoriously difficult to disentangle. In this work follow-up CT scans with pneumonitis after these treatments were explored in a radiologic pattern and a quantitative CT feature analysis. MATERIALS AND METHODS: This retrospective, single-center study included patients with pneumonitis of any grade who received chemoradiotherapy with or without durvalumab (RT-only group and RT + ICI group) for unresectable stage III NSCLC between 2011 and 2021, as well as patients with pneumonitis who received pembrolizumab as first-line therapy (ICI-only group) for stage IV NSCLC between 2017 and 2021. Clinical data and computed tomography (CT) scans were collected at baseline and follow-up. A radiologist compared CT characteristics among the three groups to identify patterns of radiotherapy-related and ICI-related pneumonitis. Furthermore, quantitative imaging features of lung damage derived from follow-up CT scans were compared between different lung regions within the same patient and across treatment groups. RESULTS: Seventy-one patients developed pneumonitis: 36/163 in the RT-only group (22.1%), 18/116 in the ICI-only group (15.5%), and 17/36 in the RT + ICI group (47.2%, p < 0.001). The ICI-only group showed involvement of more lobes vs. RT + ICI and RT-only (4.06 vs. 3.41 vs. 3.21 respectively; p = 0.03) and a trend toward more bilateral disease (83%, 65%, and 58%; p = 0.06). RT-only patients exhibited more bronchiectasis vs. RT + ICI and ICI-only (47%, 18%, and 6% respectively; p = 0.003), while consolidations were less frequent in the ICI-only group (50%, 75%, and 75%; p = 0.04). Low-grade pneumonitis (grade < 3) was more often associated with an organizing pneumonia pattern (p = 0.01), whereas higher-grade cases showed other radiologic patterns.Risk factors for high-grade pneumonitis included pre-existing interstitial lung disease (ILD; 14% vs. 2%, p = 0.03) and lower baseline diffusion capacity (52.2 ± 15.3% vs. 71.0 ± 21.4%; p = 0.004). High-grade pneumonitis developed earlier (52.5 ± 49.5 vs. 133.0 ± 101.6 days; p < 0.001) and was more frequently bilateral (100% vs. 59%; p = 0.003).Quantitative CT analysis revealed significant differences between lung regions receiving high (>10 Gy) and low (<10 Gy) radiation doses across all evaluated features. In high-dose regions, the RT + ICI group exhibited more severe lung damage than the RT-only group (e.g., entropy, p = 0.017), whereas no differences were observed in low-dose regions (p > 0.20). Imaging features from the ICI-only group most closely resembled those from high-dose regions of the RT-only group which may suggest a synergistic effect of radiotherapy and ICI in developing lung injury in the RT + ICI group. CONCLUSION: A significantly higher incidence of pneumonitis was observed in patients treated with combined RT and ICI. High-grade pneumonitis was more often bilateral, presented with distinct radiologic patterns, developed earlier, and was associated with pre-existing ILD and reduced diffusion capacity. Quantitative CT analysis confirmed that the combination of moderate- to high-dose lung irradiation with ICI therapy leads to greater severity of lung damage.
引用
- Verbeke X, Defraene G, De Wever W, et al. Pneumonitis after chemoradiotherapy and/or immunotherapy for stage III and IV non-small cell lung cancer is characterized by specific radiologic and quantitative CT features. Clin Transl Radiat Oncol. 2026. PMID: 42440401. doi:10.1016/j.ctro.2026.101215
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。